Weiye Li MD, PhDProfessor Emeritus of Ophthalmology, Drexel University College of Medicine, Philadelphia, Pennsylvania; Physician, Drexel Eye Physicians, Philadelphia, Pennsylvania
Dr. Weiye Li received his medical degree from The Second Medical College of Beijing, China, and received his doctorate from the University of Pennsylvania in Philadelphia. He completed a fellowship in retina vitreous diseases at Crozer-Chester Medical Center, Upland, Pennsylvania. Dr. Li was previously chairman of the Department of Ophthalmology at Peking Union Medical College Hospital, Beijing, China. He is widely published and has earned many honors and awards. He is also active in many organizations, including the Association of Research in Vision and Ophthalmology.
DisclosuresWeiye Li, MD, PhD has no financial arrangement or affiliation with a corporate organization or a manufacturer of a product discussed in this supplement.
Recent Contributions to PracticeUpdate:
- 2023 Top Story in Eye Care: Advances in the Management of Age-Related Macular Degeneration
- Predictors of Visual Outcomes After Vitrectomy With Subretinal Tissue Plasminogen Activator Injection in Patients With Submacular Hemorrhage
- Influence of Lesion Location on Lesion Reactivation After Initial Treatment in Patients With Neovascular AMD
- Clinical Features and Outcomes of Surgical Repair in Patients With Retinal Detachment Associated With Retinal Dialysis
- Pathogenesis, Prognosis, and Treatment for Intraretinal and Subretinal Fluid in Patients With NAAION
- Novel Surgical Approach for Big Sheet Allogenic Retinal Pigment Epithelium–Bruch Membrane Complex Transplantation Into the Subretinal Space
- Influence of Preoperative Posturing on Subfoveal Fluid Height in Patients With Macula-Off Retinal Detachments
- Predictors of Response to a Lapse in Anti-VEGF Treatment in Patients With Macular Edema Secondary to Retinal Vein Occlusion
- Real-World Outcomes of Photodynamic Therapy in Patients With Chronic Central Serous Chorioretinopathy
- Surgery vs Pneumatic Displacement in Combination With Tissue Plasminogen Activator and Antiangiogenic Agents in Patients With Submacular Hemorrhage Secondary to nAMD